Shares of Glenmark Pharma Ltd fell 2% after touching a day’s excessive of Rs 1,907.90 on 4th November. This occurred regardless that the corporate introduced that its US-based arm will launch the 8.4% Sodium Bicarbonate Injection USP. This injection is used to deal with metabolic acidosis — a situation attributable to extra acid manufacturing within the physique.
Glenmark stated its US arm will launch the 8.4% Sodium Bicarbonate Injection USP in November 2025. The injection, accessible in a 50 mEq/50 mL single-dose vial, is bioequivalent and therapeutically equal to Abbott Laboratories’ reference drug.
In accordance with IQVIA knowledge for the 12 months ending August 2025, the marketplace for this injection recorded annual gross sales of about $63.8 million. It’s used to deal with metabolic acidosis — a situation attributable to extra acid within the physique. This happens on account of points like extreme kidney illness, uncontrolled diabetes, shock, dehydration, or cardiac arrest.
Marc Kikuchi, President and Enterprise Head, North America, stated the launch expands Glenmark’s injectable portfolio. It reinforces its concentrate on offering high quality, reasonably priced remedies. Glenmark added that its injection might be marketed just for the indications authorised on its label.
At 1:08 PM, shares of Glenmark Pharma have been buying and selling 1.72% decrease at Rs 1,865.70 on NSE.
Unicorn Alerts leverages superior AI expertise to give you highly effective market predictions and actionable inventory scans. Obtain the app at this time and 10x your buying and selling & investing journey!
